Since the outbreak of the COVID‑19 pandemic, observations and scientific reports have been accumulating rapidly that sudden anosmia and taste disorders are symptoms associated with the COVID-19 infection \[[@CR1], [@CR2]\]. Recently the World Health Organization has included the loss of smell or taste as a new symptom of COVID-19 infection as have many Health Authorities after a surge of publications and press releases that pointed to anosmia as a potential screening symptom that might contribute to the decision to test suspected cases or guide quarantine instructions. Subsequently, Otolaryngologic and Rhinologic Societies have worldwide also advised to consider patients with newly acquired sudden loss of smell as potentially positive for SARS-CoV-2. Given the increase of publications concerning anosmia, and the fact that most current research is under "time-pressure" to provide insight to the pandemic, we undertook a review of the published relevant literature. The objective of this systematic review was to examine existing scientific evidence on the role of anosmia detection in the COVID-19 pandemic and highlight the areas of need for further research.

A computerized search of the PubMed/Medline and Cochrane databases was performed of all indexed studies to identify all relevant manuscripts and preprints up to May 3, 2020. Preprints' repositories included medRxiv. Combined search terms included: "COVID-19", "SARS-CoV-2", "coronavirus", "nose", "anosmia", "hyposmia", "olfactory loss", "smell loss", "taste loss", and "hypogeusia". Adjunctive searches were performed based on the studies that were identified (and their references). Studies were excluded if full texts could not be obtained.

Our search identified 18 reviewed articles published or accepted for publication \[[@CR1]--[@CR18]\] and 6 manuscript preprints (not peer-reviewed) \[[@CR19]--[@CR24]\] reporting on patients presenting sudden anosmia/taste loss in the context of COVID-19 infection (Table [1](#Tab1){ref-type="table"}). The studies took place from mid-January to mid-April. There were great methodological differences among the studies. A large epidemiological study reported on 9199 persons who were recruited for targeted testing in Iceland \[[@CR9]\]. Four large observational case series reported anosmia prevalence in COVID-19 cohorts from China \[[@CR3]\], Belgium and other European countries \[[@CR2]\], USA \[[@CR8]\], Italy \[[@CR11]\]. Five case--controlled studies compared the smell/taste loss between SARS-CoV-2 PCR-positive participants and patients PCR-positive for influenza \[[@CR4]\], a panel of respiratory viruses \[[@CR10]\], matched hospitalized controls \[[@CR6], [@CR20]\], and patients tested for influenza-like symptoms for COVID-19 \[[@CR19]\]. Five cross-sectional studies of SARS-CoV-2 + patients report on smell/taste loss in patients with varying COVID-19 disease severity \[[@CR1], [@CR5], [@CR7], [@CR21], [@CR22]\]. Four small case series and a case report of anosmic patients, most of whom had been tested for SARS-CoV-2 with various indications \[[@CR14]--[@CR18]\] and four electronic surveys about smell loss \[[@CR12], [@CR13], [@CR23], [@CR24]\] commented on the increase of the patients seeking treatment for smell loss during the COVID-19 pandemic. The electronic surveys included the AAOHNS COVID-19 Anosmia Reporting Tool (completed by healthcare providers) \[[@CR12]\], The RADAR COVID-19, an online app for the UK general population \[[@CR23]\] and two surveys prompted by patients' queries about smell loss (in UK \[[@CR13]\] and Iran \[[@CR24]\]), one reporting on a small percentage tested for SARS-CoV-2.Table 1Studies on the role of smell and taste disorders in suspected COVID‑19Author source *Country*Study typeNo of patientsParticipantsAnosmia %Course of anosmiaLevel of evidenceGiacomelli A, et al. \[[@CR1]\]Clin Infect Dis*Italy*Cross-sectional59SARS-CoV-2+, hospitalized33.9% taste/smell loss18.6% both20.3% pre-admission anosmiaIVLechien et al. \[[@CR2]\]Eur Arch Otorhinolaryngol*BelgiumFranceItaly, Spain*Case series observational417 mild-to-moderate COVID-19SARS-CoV-2+, hospitalized and home85.6% smell loss79.6% anosmic11.8% initial symptomTaste loss in 88.8%72.6% recovered smell in 8 dIVMao L, et al. \[[@CR3]\]JAMA Neurol *China*Case series, observational214SARS-CoV-2+, hospitalized5.1%6.3% in mild disease5.6% taste lossIVBeltrán-Corbellini Α, et al. \[[@CR4]\]Eur J Neurol*Spain*Case-control79 COVID-1940 controlsSARS-CoV-2+, hospitalizedinfluenza controls31.6% in COVID-1912.5% in controls (OR 21.4)35.5% initial symptom35.4% taste loss12.9% nasal obstruction56.7% recovery (mean: 7.5 d)IIISpinato J, et al. \[[@CR5]\]JAMA*Italy*Cross-sectional202SARS-CoV-2+, home64.4%3% only symptom36.1% nasal obstructionIVMoein ST, et al. \[[@CR6]\]Int Forum Allergy Rhinol*Iran*Case--control60 patients60 controlsSARS-CoV-2+, hospitalizedmatched controls olfactory test29% reported a loss58% tested anosmic/severely hyposmic18% of controls mild hyposmiaNot an initial symptom24% taste lossIIIYan CH, et al. \[[@CR7]\]Int Forum Allergy Rhinol*USA*Cross-sectional59 SARS-CoV-2+203 SARS-CoV-2−suspect caseSARS-CoV-2+ mostly home68% in SARS-CoV-2+16% in SARS-CoV-2−Taste loss71% in SARS-CoV-2+17% in SARS-CoV-2−72.5% improvement18% \< 1 W, 37.5% 1--2 WIVYan CH, et al. \[[@CR8]\]Int Forum Allergy Rhinol*USA*Case series, observational128SARS-CoV-2+,20% hospitalized26.9% in hospitalized patients66.7% in home-treated patientsTaste loss23.1% in hospitalized vs 62.7% in home-treatedPatients with loss of smell were 10 times less likely to be admittedIVGudbjartsson DF, et al. \[[@CR9]\]N Engl J Med*Iceland*Epidemiological1044Targeted TestsSARS-CoV-2+11.5%High level epidemiologicalWee LE, et al. \[[@CR10]\]Eur Arch Otorhinolaryngol*Singapore*Case-control870 suspect case154 SARS-CoV-2+71 other viruses+, rhinovirus, influenza, adenoviruses, coronavirusesSuspect casesSARS-CoV-2+ routine panel of respiratory viruses5% in suspect cases22.7% in SARS-CoV-2+2.8% in other viruses (OR 10.14)8.6% only symptom28.5% rhinorrheaSmell loss as screening:98.7% specificity, 22.7% sensitivityIIIVaira LA, et al. \[[@CR11]\]Head Neck*Italy*Case series observational72SARS-CoV-2+22 hospitalized47 home, healthcare personnelOlfactory/taste test73%18% initial symptom66% recovery at evaluation (mean 19 d) most recovered earlier than 5 dIVKaye R, et al. \[[@CR12]\]Otolaryngol Head Neck Surg*USA*Online AAOHNS Reporting Tool237 physician-submitted cases of COVID-19 related smell/taste lossThe AAOHNS COVID-19 Anosmia Reporting ToolAll27% initial symptom25% nasal obstruction18% rhinorrheaMean time to improvement of 7.2 dIVHopkins C, et al. \[[@CR13]\]Rhinology*UK*Survey prompted by queries about anosmia2428 reporting new onset anosmia80 had been tested for SARS-CoV-2, 74% were positiveAllIVHeidari F, et al. \[[@CR14]\]Rhinology*Iran*Anosmia case series23Sudden anosmia SARS-CoV-2+All83% initial symptom69.6% only symptom75% improvement in 2 weeksIVGilani G, et al. \[[@CR15]\]Medical Hypothesis*Iran*Anosmia case series8Sudden anosmia5 tested, SARS-CoV-2+AllAnosmia followed other symptomsIVOttaviano G, et al. \[[@CR16]\]Rhinology*Italy*Anosmia case series6 healthcare personnelSudden anosmiaSARS-CoV-2+All75% initial symptomImprovement in 15 dIVGane SB, et al. \[[@CR17]\]Rhinology*UK*Anosmia case series11Sudden anosmia 1 tested, SARS-CoV-2+All55.5% only symptomIVEliezer M, et al. \[[@CR18]\] JAMA Otolaryngol Head Neck*France*Case report1SARS-CoV-2+ CT, MRIAnosmia without nasal obstructionBilateral inflammatory obstruction of the olfactory cleftsIVHaehner A, et al. \[[@CR19]\]medRxiv*Germany*Cross-sectional controlled500 suspect cases34 SARS-CoV-2+466 SARS-CoV-2−Suspect casesAnosmic were 22 SARS-CoV-2+49 SARS-CoV-2−13.8% in all suspect cases64.7% in SARS-CoV-2+10.1% in SARS-CoV-2−Anosmic pts had less severe COVID-194.5% initial symptomCOVID-19 anosmic patients had less nasal obstruction and rhinorrheaSmell loss as screening:65% sensitivity, 90% specificityIIIHornuss D, et al. \[[@CR20]\]medRxiv*Germany*Cross-sectional controlled45 patients45 controlsSARS-CoV-2 + , hospitalizedHospitalized controlsOlfactory test (Sniffin' Stick12)SARS-CoV-2+49% reported smell lossTested anosmic 40%, hyposmic 40%0% of controls reported anosmiaIIILevinson R, et al. \[[@CR21]\]medRxiv*Israel*Cross-sectional42SARS-CoV-2+ hospitalized mild COVID-1935.7%33.3% taste lossAnosmia follow-up/4d: 73.3% recovery, median duration 7.6 dIVLechien J, et al. \[[@CR22]\]medRxiv*Belgium*Cross-sectional78 reporting sudden anosmia49 SARS-CoV-2+Sudden anosmiaSARS-CoV-2+Olfactory test, 46ptsAllAnosmia ≤ 12 d:87.5% SARS-CoV-2+Lasting: 23% SARS-CoV-2+46.2% nasal obstruction24% of reported anosmic patients were normosmic on olfactory testingIVMenni C, et al. \[[@CR23]\]medRxiv*UK*Online appCommunity surveyFor general population1702 responders reported having being tested579 SARS-CoV-2+1123 SARS-CoV-2−Responders to RADAR COVID-19, an app asking about COVID-19 symptoms59% in SARS-CoV-2+18% in SARS-CoV-2−IVBagheri SHR, et al. \[[@CR24]\]medRxiv*Iran*Online community survey10069 reporting new onset anosmiaVolunteers reporting anosmia, general populationAnosmia increased as did COVID-19 positivity in provinces of IranIV*No* number; Level of evidence of prognostic studies; *d* days; *w* weeks; *AAOHNS* American Academy of Otolaryngology--Head and Neck Surgery; tested: with RT-PCR for SARS-CoV-2+

*Prevalence of smell loss:* A large epidemiological study reported a prevalence of 11.5% for smell loss in 1044 SARS-CoV-2 + identified through targeted tests \[[@CR9]\]. Four observational case series reported smell loss in their studied cohorts at 5.1% (hospitalized patients) \[[@CR3]\], 26.9% (hospitalized patients) and 66.7% (home-treated patients) \[[@CR8]\], 73% (hospitalized and home-treated patients) \[[@CR11]\], and 85.6% (hospitalized and home-treated patients) \[[@CR2]\]. The observed discrepancies most likely are related to varying research methods and possible patient selection biases. A significant proportion of the cohort in the studies reporting high anosmia prevalence was healthcare personnel \[[@CR2], [@CR11]\]. Cross-sectional studies found the prevalence of anosmia to be at 33.9% \[[@CR1]\] and 35.7% \[[@CR21]\] for hospitalized patients and 64.4% \[[@CR5]\] and 68% \[[@CR7]\] for out-patients. Smell loss prevalence was compared between COVID-19 patients and control groups in five case-controlled studies: 22.7% of COVID-19 patients compared to 2.8% of patients positive for a panel of respiratory viruses \[[@CR10]\], 31.6% of COVID-19 compared to 12.5% of influenza \[[@CR4]\], 29% of COVID-19 patients compared to 18% for controls \[[@CR6]\], 49% compared to 0% for controls \[[@CR20]\], and 64.7% of COVID-19 patients compared to 10.1% for respiratory viral illness \[[@CR19]\]. The smell loss as a screening symptom was found to show a high specificity and moderate sensitivity for the detection of COVID-19 infection \[[@CR10], [@CR19]\].

*Clinical characteristics:* Most of the studies reported either smell loss or smell plus taste loss. As a presenting symptom, anosmia was rated from 0 to 35%. All the studies that comment on the course of anosmia report quick recovery, in 7--10 days \[[@CR2], [@CR4], [@CR7], [@CR11], [@CR14], [@CR16], [@CR21]\]. Nasal obstruction was found at rates ranging from 12.9% to 46% and rhinorrhea from 18% to 28.5%.

While great methodological differences were noted in the reviewed studies, a significant prevalence of anosmia is reported in COVID-19 patients, and controlled studies indicate that anosmia is more common in COVID-19 patients than in patients suffering from other respiratory infections or controls, taking into account seasonal patterns of olfactory dysfunction. Less severe COVID-19 disease is related to a greater prevalence of anosmia. Olfactory testing and treatment decisions should take into account that quick recovery of the smell loss may be expected in most COVID-19 cases.
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